Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier.

[1]  David S. Miller,et al.  Restoring Blood-Brain Barrier P-Glycoprotein Reduces Brain Amyloid-β in a Mouse Model of Alzheimer's Disease , 2010, Molecular Pharmacology.

[2]  David S. Miller,et al.  17-β-Estradiol: A Powerful Modulator of Blood–Brain Barrier BCRP Activity , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[3]  David S. Miller,et al.  Activation of PKC Isoform βI at the Blood–Brain Barrier Rapidly Decreases P-Glycoprotein Activity and Enhances Drug Delivery to the Brain , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[4]  M. Toborek,et al.  Intact Lipid Rafts Regulate HIV-1 Tat Protein-Induced Activation of the Rho Signaling and Upregulation of P-Glycoprotein in Brain Endothelial Cells , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[5]  David J. Begley,et al.  Structure and function of the blood–brain barrier , 2010, Neurobiology of Disease.

[6]  David S. Miller,et al.  Rapid, Reversible Modulation of Blood–Brain BarrierP-Glycoprotein Transport Activity by Vascular Endothelial Growth Factor , 2010, The Journal of Neuroscience.

[7]  V. Longo,et al.  Expression and distribution of CYP3A genes, CYP2B22, and MDR1, MRP1, MRP2, LRP efflux transporters in brain of control and rifampicin-treated pigs , 2010, Molecular and Cellular Biochemistry.

[8]  Sarah Vautier,et al.  ABCB1: the role in Parkinson's disease and pharmacokinetics of antiparkinsonian drugs , 2009, Expert opinion on drug metabolism & toxicology.

[9]  M. Hall,et al.  Imaging the Function of P‐Glycoprotein With Radiotracers: Pharmacokinetics and In Vivo Applications , 2009, Clinical pharmacology and therapeutics.

[10]  A. Hartz,et al.  Signaling to P-glycoprotein-A new therapeutic target to treat drug-resistant epilepsy? , 2009, Drug news & perspectives.

[11]  N. Shaik,et al.  P-glycoprotein and Breast Cancer Resistance Protein Influence Brain Distribution of Dasatinib , 2009, Journal of Pharmacology and Experimental Therapeutics.

[12]  Friederike Neumann,et al.  Age dependency of cerebral P-gp function measured with (R)-[11C]verapamil and PET , 2009, European Journal of Clinical Pharmacology.

[13]  S. Hladky,et al.  Decreased expression of multidrug efflux transporters in the brains of GSK-3β transgenic mice , 2009, Brain Research.

[14]  L. Lue,et al.  ABCG2 Is Upregulated in Alzheimer's Brain with Cerebral Amyloid Angiopathy and May Act as a Gatekeeper at the Blood–Brain Barrier for Aβ1–40 Peptides , 2009, The Journal of Neuroscience.

[15]  I. Romero,et al.  P-Glycoprotein and Breast Cancer Resistance Protein Restrict Apical-to-Basolateral Permeability of Human Brain Endothelium to Amyloid-β , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[16]  M. Ott,et al.  Pregnane X Receptor (PXR) Regulates P-Glycoprotein at the Blood-Brain Barrier: Functional Similarities between Pig and Human PXR , 2009, Journal of Pharmacology and Experimental Therapeutics.

[17]  K. Bock,et al.  Coordinate regulation of human drug-metabolizing enzymes, and conjugate transporters by the Ah receptor, pregnane X receptor and constitutive androstane receptor. , 2009, Biochemical pharmacology.

[18]  Joseph W. Polli,et al.  An Unexpected Synergist Role of P-Glycoprotein and Breast Cancer Resistance Protein on the Central Nervous System Penetration of the Tyrosine Kinase Inhibitor Lapatinib (N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016) , 2009, Drug Metabolism and Disposition.

[19]  S. Moochhala,et al.  Involvement of ROS in BBB dysfunction , 2009, Free radical research.

[20]  Y. Xia,et al.  Glutathione depletion upregulates P-glycoprotein expression at the blood-brain barrier in rats. , 2009, The Journal of pharmacy and pharmacology.

[21]  W. Banks,et al.  Lipopolysaccharide Impairs Blood–Brain Barrier P-glycoprotein Function in Mice Through Prostaglandin- and Nitric Oxide-Independent Pathways , 2009, Journal of Neuroimmune Pharmacology.

[22]  C. Daumas-Duport,et al.  ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood–brain barrier , 2008, Journal of neurochemistry.

[23]  Randall W. Engle,et al.  Air pollution, cognitive deficits and brain abnormalities: A pilot study with children and dogs , 2008, Brain and Cognition.

[24]  D. Roberts,et al.  A critical overview of the influence of inflammation and infection on P-glycoprotein expression and activity in the brain , 2008, Expert opinion on drug metabolism & toxicology.

[25]  Christopher M Waters,et al.  Dexamethasone increases expression and activity of multidrug resistance transporters at the rat blood-brain barrier. , 2008, American journal of physiology. Cell physiology.

[26]  S. Hladky,et al.  Activation of β‐catenin signalling by GSK‐3 inhibition increases p‐glycoprotein expression in brain endothelial cells , 2008, Journal of neurochemistry.

[27]  M. Block,et al.  Diesel exhaust particles induce oxidative stress, proinflammatory signaling, and P‐glycoprotein up‐regulation at the blood‐brain barrier , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  R. Béliveau,et al.  Regulation of brain endothelial cells migration and angiogenesis by P-glycoprotein/caveolin-1 interaction. , 2008, Biochemical and biophysical research communications.

[29]  David S. Miller,et al.  Modulation of P-Glycoprotein at the Blood-Brain Barrier: Opportunities to Improve Central Nervous System Pharmacotherapy , 2008, Pharmacological Reviews.

[30]  Atsushi Ose,et al.  Quantitative Investigation of the Role of Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting Brain and Testis Penetration of Xenobiotic Compounds , 2008, Drug Metabolism and Disposition.

[31]  Heidrun Potschka,et al.  Seizure-Induced Up-Regulation of P-Glycoprotein at the Blood-Brain Barrier through Glutamate and Cyclooxygenase-2 Signaling , 2008, Molecular Pharmacology.

[32]  G. M. Pollack,et al.  Coordinated Nuclear Receptor Regulation of the Efflux Transporter, Mrp2, and the Phase-Ii Metabolizing Enzyme, GSTπ, at the Blood—Brain Barrier , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[33]  W. Haefeli,et al.  Comparison of the induction of P-glycoprotein activity by nucleotide, nucleoside, and non-nucleoside reverse transcriptase inhibitors. , 2008, European journal of pharmacology.

[34]  B. Zlokovic.  The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders , 2008, Neuron.

[35]  J. Pascussi,et al.  The tangle of nuclear receptors that controls xenobiotic metabolism and transport: crosstalk and consequences. , 2008, Annual review of pharmacology and toxicology.

[36]  D. Roberts,et al.  A critical overview of the influence of inflammation and infection on P-glycoprotein expression and activity in the brain. , 2008, Expert opinion on drug metabolism & toxicology.

[37]  S. Teng,et al.  Regulation of transporters by nuclear hormone receptors: implications during inflammation. , 2008, Molecular pharmaceutics.

[38]  D. Shen,et al.  Where is the evidence that p‐glycoprotein limits brain uptake of antiepileptic drug and contributes to drug resistance in epilepsy? , 2007, Epilepsia.

[39]  Jos H Beijnen,et al.  P-Glycoprotein and Breast Cancer Resistance Protein: Two Dominant Transporters Working Together in Limiting the Brain Penetration of Topotecan , 2007, Clinical Cancer Research.

[40]  H. Kroemer,et al.  MDR1‐P‐Glycoprotein (ABCB1) Mediates Transport of Alzheimer’s Amyloid‐β Peptides—Implications for the Mechanisms of Aβ Clearance at the Blood–Brain Barrier , 2007, Brain pathology.

[41]  W. Haefeli,et al.  Localization of the Human Breast Cancer Resistance Protein (BCRP/ABCG2) in Lipid Rafts/Caveolae and Modulation of Its Activity by Cholesterol in Vitro , 2007, Journal of Pharmacology and Experimental Therapeutics.

[42]  M. Seelbach,et al.  Peripheral inflammatory hyperalgesia modulates morphine delivery to the brain: a role for P‐glycoprotein , 2007, Journal of neurochemistry.

[43]  D. Greenblatt,et al.  Induction of P‐glycoprotein expression and activity by ritonavir in bovine brain microvessel endothelial cells , 2007, The Journal of pharmacy and pharmacology.

[44]  David S. Miller,et al.  Tumor Necrosis Factor α and Endothelin-1 Increase P-Glycoprotein Expression and Transport Activity at the Blood-Brain Barrier , 2007, Molecular Pharmacology.

[45]  W. Löscher,et al.  Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein , 2007, Neuropharmacology.

[46]  C. Henríquez-Roldán,et al.  Pediatric Respiratory and Systemic Effects of Chronic Air Pollution Exposure: Nose, Lung, Heart, and Brain Pathology , 2007, Toxicologic pathology.

[47]  W. Löscher,et al.  Valproic Acid Is Not a Substrate for P-glycoprotein or Multidrug Resistance Proteins 1 and 2 in a Number of in Vitro and in Vivo Transport Assays , 2007, Journal of Pharmacology and Experimental Therapeutics.

[48]  D. Gingras,et al.  Modulation of p‐glycoprotein function by caveolin‐1 phosphorylation , 2006, Journal of neurochemistry.

[49]  David S. Miller,et al.  Tumor necrosis factor alpha and endothelin-1 increase P-glycoprotein expression and transport activity at the blood-brain barrier. , 2007, Molecular pharmacology.

[50]  G. M. Pollack,et al.  In Vivo Activation of Human Pregnane X Receptor Tightens the Blood-Brain Barrier to Methadone through P-Glycoprotein Up-Regulation , 2006, Molecular Pharmacology.

[51]  M. Toborek,et al.  HIV-TAT Protein Upregulates Expression of Multidrug Resistance Protein 1 in the Blood–Brain Barrier , 2006, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[52]  R. Bendayan,et al.  Multidrug Resistance-Associated Proteins: Expression and Function in the Central Nervous System , 2006, Pharmacological Reviews.

[53]  A. Aguzzi,et al.  Cerebrovascular P-glycoprotein expression is decreased in Creutzfeldt–Jakob disease , 2006, Acta Neuropathologica.

[54]  G. Fricker,et al.  Rapid Modulation of P-Glycoprotein-Mediated Transport at the Blood-Brain Barrier by Tumor Necrosis Factor-α and Lipopolysaccharide , 2006, Molecular Pharmacology.

[55]  J. Schellens,et al.  Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. , 2006, Trends in pharmacological sciences.

[56]  K. Jin,et al.  From angiogenesis to neuropathology , 2005, Nature.

[57]  Liang-Shang Gan,et al.  Breast cancer resistance protein in pharmacokinetics and drug–drug interactions , 2005, Expert opinion on drug metabolism & toxicology.

[58]  Wolfgang Löscher,et al.  Drug resistance in brain diseases and the role of drug efflux transporters , 2005, Nature Reviews Neuroscience.

[59]  M. Toborek,et al.  HIV‐Tat protein induces P‐glycoprotein expression in brain microvascular endothelial cells , 2005, Journal of neurochemistry.

[60]  T. Davis,et al.  The Blood-Brain Barrier/Neurovascular Unit in Health and Disease , 2005, Pharmacological Reviews.

[61]  M. Brodie,et al.  Lack of Association between the C3435T Polymorphism in the Human Multidrug Resistance (MDR1) Gene and Response to Antiepileptic Drug Treatment , 2005, Epilepsia.

[62]  A. V. van Herwaarden,et al.  Sex-Dependent Expression and Activity of the ATP-Binding Cassette Transporter Breast Cancer Resistance Protein (BCRP/ABCG2) in Liver , 2005, Molecular Pharmacology.

[63]  C. Klaassen,et al.  Tissue distribution and hormonal regulation of the breast cancer resistance protein (Bcrp/Abcg2) in rats and mice. , 2004, Biochemical and biophysical research communications.

[64]  E. Masliah,et al.  Altered P‐Glycoprotein Expression in AIDS Patients with HIV Encephalitis , 2004, Journal of neuropathology and experimental neurology.

[65]  G. Li,et al.  Nanometer size diesel exhaust particles are selectively toxic to dopaminergic neurons: the role of microglia, phagocytosis, and NADPH oxidase , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[66]  I. Scheffer,et al.  Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy , 2004, Neurology.

[67]  P. Wielinga,et al.  Mrp4 Confers Resistance to Topotecan and Protects the Brain from Chemotherapy , 2004, Molecular and Cellular Biology.

[68]  G. Fricker,et al.  Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the blood-brain barrier. , 2004, Molecular pharmacology.

[69]  G. Fricker,et al.  Rapid Regulation of P-Glycoprotein at the Blood-Brain Barrier by Endothelin-1 , 2004, Molecular Pharmacology.

[70]  J. Beijnen,et al.  Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein. , 2004, European journal of cancer.

[71]  M. Barrand,et al.  Signalling pathways influencing basal and H2O2‐induced P‐glycoprotein expression in endothelial cells derived from the blood–brain barrier , 2003, Journal of neurochemistry.

[72]  Yuichi Sugiyama,et al.  Impact of Drug Transporter Studies on Drug Discovery and Development , 2003, Pharmacological Reviews.

[73]  Willem Boogerd,et al.  Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[74]  D. Goldstein,et al.  Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. , 2003, The New England journal of medicine.

[75]  Armin Buschauer,et al.  Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. , 2002, The Journal of clinical investigation.

[76]  Christiane Kunert-Keil,et al.  Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. , 2002, Pharmacogenetics.

[77]  M. Barrand,et al.  P‐glycoprotein expression in rat brain endothelial cells: 
evidence for regulation by transient oxidative stress , 2002, Journal of neurochemistry.

[78]  David S. Miller.  Xenobiotic export pumps, endothelin signaling, and tubular nephrotoxicants—a case of molecular hijacking , 2002, Journal of biochemical and molecular toxicology.

[79]  S. Cole,et al.  Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. , 2001, Toxicology.